Morgan Stanley upgrades Dasa to buy and targets R$ 4.80

Morgan Stanley upgraded its recommendation on Brazilian healthcare company Dasa from neutral to overweight (buy) and raised its price target from R$ 3.00 to R$ 4.80. Following the report on Thursday, September 24, 2026, Dasa shares rose 6.81% to R$ 3.45 at 10:14 a.m. in Brasília.

The bank highlighted improving cash generation and clearer deleveraging visibility following second-quarter results. Analysts noted consistent growth in the diagnostics unit, lower administrative costs, and a more capital-efficient expansion model, which could reduce debt without requiring asset sales. Morgan Stanley forecasts that net debt to EBITDA leverage will fall from 3 times in 2026 to 2 times by 2028.

In the same sector review, Morgan Stanley raised price targets for RD Saúde (to R$ 27.50 from R$ 26.00), Hypera (to R$ 32.50 from R$ 31.00), Fleury (to R$ 23.20 from R$ 19.10), and Blau Farmacêutica (to R$ 11.50 from R$ 10.50). Conversely, it cut Hapvida's target from R$ 11.00 to R$ 8.00 due to judicial expenses.